Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Series A Senior Preferred Stock Purchase Agreement
As described in the Current Report on Form 8-K filed by the Issuer with the Commission on February 25, 2022, on February 24, 2022 (the “Closing Date”), the Issuer entered into a Series A Senior Preferred Stock Purchase Agreement (“Purchase Agreement”) with the purchasers signatory thereto (the “Investors”), including the Reporting Persons, pursuant to which the Investors purchased from the Company, in the aggregate, 165,000 shares of Series A Senior Preferred Stock with an initial stated value of $1,000 per share, or $165,000,000 of stated value in the aggregate (“Series A Preferred Stock”), and warrants to purchase up to 11,538,401 shares of common stock of the Company, for an aggregate purchase price of $163,350,000 (“Preferred Stock Financing Proceeds”; and such transaction, the “Preferred Stock Financing”). The Preferred Stock Financing Proceeds reflected an original issue discount of 1.0% of the stated value of the Series A Preferred Stock. Pursuant to the terms of the Purchase Agreement, the Reporting Persons also acquired (i) an aggregate 3,135,928 warrants entitling each holder thereof to purchase one share of Class A common stock, $0.0001 par value per share of the Issuer (“Class A Common Stock”) at an exercise price of $0.01 (the “Penny Warrants”) and (ii) an aggregate 2,090,619 warrants entitling each holder thereof to purchase one share of Class A Common Stock at an exercise price of $3.00 (the “$3 Warrants”).
This summary is qualified in its entirety by reference to the text of the Purchase Agreement, which is attached as Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed by the Issuer with the Commission on February 25, 2022, and is incorporated herein by reference.
Warrants and Warrant Agreement
In connection with the Preferred Stock Financing, the Issuer agreed to issue to the Investors: (i) an aggregate 5,226,546 $3.00 Warrants, exercisable for a five-year period from the Closing Date; and (ii) an aggregate 6,271,855 Penny Warrants, exercisable for a five-year period from the Closing Date. Such number of shares of Class A Common Stock purchasable pursuant to the $3 Warrants and the Penny Warrants may be adjusted from time to time as set forth in the Warrant Agreement (as defined below). The Reporting Persons acquired (i) an aggregate 3,135,928 Penny Warrants and (ii) an aggregate 2,090,619 $3 Warrants.
On the Closing Date, the Issuer also entered into a Warrant Agreement with Continental Stock Transfer & Trust Company, as warrant agent. Under the terms of the Warrant Agreement, the Investors are entitled to, among other things, registration rights with respect to the Class A Common Stock underlying the Penny Warrants and $3 Warrants, anti-dilution protection (subject to customary carve-outs) and pre-emptive rights.
This summary is qualified in its entirety by reference to the text of the Warrant Agreement, which is attached as Exhibit 4.1 to the Issuer’s Current Report on Form 8-K filed by the Issuer with the Commission on February 25, 2022, and is incorporated herein by reference.
Investors’ Rights Agreement
In connection with the Preferred Stock Financing, the Issuer entered into an Investors’ Rights Agreement with the Investors (the “Investors’ Rights Agreement”) as of the Closing Date. The Investors’ Rights Agreement sets forth the Investors’ right to designate one director to the Issuer’s board of directors (subject to certain conditions) and to receive certain quarterly and annual financial and other information of the Issuer. The Investors’ Rights Agreement also sets forth restrictions on transfer of shares of Series A Preferred Stock by the Investors and rights of first refusal in favor of any holder that, individually or together with its affiliates, holds, in the aggregate, at least 25% of the then-outstanding Series A Preferred Stock. The Issuer also agreed in the Investors’ Rights Agreement to pay expenses incurred by Investors in connection with (i) any amendment, modification or waiver of a provision of any Transaction Document and (ii) the enforcement by the Investors of any of their rights in connection with the Transaction Documents, in each case subject to the terms and conditions set forth in the Investors’ Rights Agreement.
This summary is qualified in its entirety by reference to the text of the Investors’ Rights Agreement, which is attached as Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed by the Issuer with the Commission on February 25, 2022, and is incorporated herein by reference.